GSK to buy up research and development company

Drug maker to buy shares it doesn't own in Cellzome for $99 million

LONDON — GlaxoSmithKline is acquiring the remainder of a privately owned research and development company, GSK said Tuesday.

The British drug maker announced that it would buy the shares of Cellzome it doesn't already own for $99 million. Cellzome has labs in the United Kingdom and Germany, and will become part of GSK's research and development organization. The company, of which GSK currently owns 19.98%, develops technologies for profiling compounds in cells and patient samples.

"The acquisition of Cellzome adds significantly to our scientific capabilities and capacity to characterize drug targets, and provides the opportunity to further enhance GSK's ability to bring medicines to patients in a more effective manner," GSK SVP platform and technology science John Baldoni said.

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.